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Congenital heart defects (CHD) are the commonest congenital malformations and remain a major 
cause of neonatal mortality and morbidity in the developed world.1,2  Critical congenital heart 
defects (CCHD) are the most serious form of CHD with an incidence of between 2 and 3 per 1,000 
live births.3  Babies with CCHD  are at risk of cardiovascular collapse, acidosis and death in the first 
few days of life, usually following closure of the ductus arteriosus  and therefore early diagnosis is 
essential to reduce the possibility of these complications and also to improve outcome following 
cardiac surgery.1,2  
In high-income countries most babies are routinely screened for CCHD using antenatal ultrasound 
scanning and postnatal physical examination. However, both of these procedures have a relatively 
low detection rate and up to a third of babies with CCHD may be discharged from hospital before a 
diagnosis is made. 4,5 
Pulse oximetry (PO) measures blood oxygen saturations and is a well-established, accurate,  non-
invasive  method of detecting low oxygen levels (hypoxaemia).1,2  The rationale for using PO to 
screen for CCHD is that hypoxaemia is present in the majority of cases of CCHD, but the degree of 
desaturation is often comparatively mild and may be clinically undetectable, even by experienced 
clinicians.6  Therefore, the addition of PO screening (POS) following delivery will detect those babies 
with hypoxaemia, who can then be assessed and the presence of a CCHD established before the 
babies develops acute collapse.1   
Proof of concept and feasibility of POS was first established by a number of small single centre 
studies in the early 2000s, but the low prevalence of CCHD in these studies meant that there was 
insufficient evidence to precisely define the test accuracy and firm recommendations for routine 
screening could not be made.2,7  Between 2008 and 2012 several large European studies5-9 provided 
sufficient, robust evidence of test accuracy which could reliably inform the possible introduction of 
routine POS.  
 In 2012, a systematic review and meta-analysis of all available evidence (including nearly 230,000 
screened babies) concluded that pulse oximetry screening was a moderately sensitive, highly specific 
test for detection of CCHD, which met the criteria for universal screening.13 In 2014, the world’s 
largest POS study involving over 120,000 babies from China14 demonstrated similar findings which 
essentially removed any remaining uncertainties about the performance of PO screening.15   
The addition of POS reduces the ‘diagnostic gap’ for CCHD10 (i.e. those babies who are not detected 
by existing screening methods) and when POS is combined with antenatal ultrasound scanning and 
the newborn physical examination between 92 and 96% of babies with CCHD are identified in a 
timely manner.16  
Attitudes towards POS are changing and acceptance of the potential benefits is becoming more 
widespread. In 2012, a Lancet editorial commented ‘…surely, the question now is not “why should 
pulse oximetry screening be introduced?” but “why should such screening not be introduced more 
widely?”.’17 The papers within this special edition book for the International Journal of Neonatal 
Screening address many of the broader aspects of POS beyond the basic test accuracy; topics include 
acceptability, cost-effectiveness, screening in different settings - such as outside the newborn 
nursery environment and at altitude – and, importantly, implementation of POS in different 
countries and clinical settings and establishing a screening system which suits the local population. 
Giving appropriate information and assessing the acceptability of any screening test - both to the 
patients involved and to the clinical staff who administer it - is vital if it is to be successful. Previous 
studies have shown that POS is acceptable to parents and clinical staff 12,18,19  and also that it does 
not appear to create additional anxiety in the mothers (including those who have a false positive 
result).18 In this special edition, Cloete et al report feedback from parents on both the information 
they received prior to testing and their overall satisfaction of POS during a pilot screening study in 
New Zealand.20  The cultural diversity and the mainly midwifery-led maternity system in this country 
make the positive responses received particularly pertinent. As part of their extensive overview of 
the implementation process of POS in the USA – the first country to legislate for mandatory POS of 
all newborns - Wandler and Martin also report on their systematic approach to addressing the issues 
raised by such a huge undertaking.21  
As well as being acceptable a new screening test must also be shown to be cost-effective. A number 
of previous studies in different countries have tried to address this issue. 9, 22-24,  
In their review of this work in this special edition, Scott Grosse and colleagues provide a 
comprehensive analysis of the available evidence including a revised estimate of cost (based on 
recent improved survival figures from the US following the introduction of POS) estimating that the 
cost could be as low as USD 12 000 per life-year gained.25 
Switzerland, Ireland and Poland were the first countries to recommend routine POS16,26 and in 2011, 
as described above, the USA was the first country to mandate this test.27,28 
Over the past five years an increasing number of countries including Canada,29  the Nordic 
countries,30 Saudi Arabia, Abu Dhabi and Sri Lanka26 have recommended routine screening. In 
Europe, significant progress has been made by a multi-national group of clinicians working towards a 
Europe-wide implementation of PO screening 31 and recently publishing a European consensus 
statement, endorsed by leading figures from European Paediatric and Neonatal Societies.32 In this 
special edition, further recommendations are published from Germany33 and South and Central 
America34 in addition to a local study from Valencia Spain,35  which was one of the precursors to the 
recent Spanish recommendation.36  In the UK, almost half of all maternity units are screening37 but 
as yet there is no National recommendation. In Australia, a different approach has been taken; in 
this special edition Martin Kluckow suggests that pulse oximetry should be considered a ‘routine 
vital sign’ of general neonatal well-being rather than a test for a specific target such as CCHD.38  This 
allows individual hospitals to screen in a manner which suits them and might make the process 
simpler and potentially more acceptable; an approach which seems to have worked in Australia but 
in response Gentles et al argue that a structured National recommendation would ensure a more 
equitable service to the whole population.39  Kluckow’s reply indicates the fact that National 
recommendations are often rather slow and cumbersome and babies may miss out on screening 
until the recommendation is sanctioned.40 
Screening pathways (or algorithms) for PO screening within the published studies are variable.7,13,41,42 
The main differences are i) site of saturation measurement (the use of a single [post-ductal] 
saturation measurement or measuring both pre- and post-ductal saturations) and ii) the timing of 
screening (before or after 24 hours of age).  
Screening algorithms which use only single post-ductal measurement are potentially quicker and 
easier, but investigation of the data from these studies and those using both pre- and post-ductal 
saturations show that a small number of babies with CCHD may be missed by using only a single 
post-ductal measurements.16, 41,42  With large populations this number may become significant and 
the benefits of using two measurements may to outweigh the potential minor disadvantages.16,40,42  
Most of the recent recommendations advocate dual site measurements, but Riede and colleagues 
recommend post-ductal saturation measurement only.33  An interesting alternative strategy is 
proposed by Walsh and Ballweg from Tennessee  who advocate post-ductal saturations with a 
higher threshold (97%) for the initial screen and then pre and post-ductal saturations for those who 
require a repeat. 44  
As with any screening test it is important to consider the number of false positives (those babies 
who have a positive test but do not have CCHD) and the timing of the screen affects the number of 
false positive screens.13, 41 Later screening (>24 hours) has a lower rate of false positive tests,13,41  
however, between 30 and 80% of false positive babies have a significant respiratory or infective 
condition or non-critical CHD.16,25,42,43  Earlier screening is mandatory in countries (such as the UK 
where the majority of babies are discharged within 24 hours after birth or in the Netherlands where 
many babies are born outside of the hospital environment).  In addition, screening after 24 hours of 
age may result in up to half of babies with CCHD presenting before POS occurs, sometimes with an 
acute deterioration.16,42  These factors must be considered carefully; although a lower number of 
false positives is advantageous in a screening test, if the majority of false positives have a serious 
non-cardiac condition which requires urgent treatment this is clearly a significant additional 
benefit.19  In addition, later screening  - after 24 hours - may lead to more babies with CCHD 
becoming seriously unwell before testing takes place which defeats the purpose of screening.16,42  As 
more countries engage with POS and high quality outcome data are collected, the nuances of 
modifying and refining the screening algorithms can be modelled with greater precision. 
Screening babies born outside of the nursery e.g. at home, in a midwifery-led birthing centre or on 
the NICU, present particular challenges;  homebirths rates are increasing and midwifery staff often 
leave mother and baby shortly after birth, which means that testing must take place within a couple 
of hours.  However, screening babies in this situation has been shown to be both feasible and 
acceptable in a small UK study45 and a much larger Dutch study.46,47  In this special edition Narayen 
and colleagues present their experience screening such babies in the Netherlands48  and Kim et al 
report their findings of screening newborns on the NICU at moderate altitude (1700m).49  
 
In summary, PO screening is feasible, cost-effective and acceptable, and reduces the diagnostic gap 
for CCHD. This special edition of the International Journal of Neonatal Screening focuses on a 
number of issues which are entirely relevant to those who might be considering introducing such 
screening. 
A universal programme of PO screening in newborns will increase the detection of CCHD, and 
importantly, it has also been shown to be useful in identifying other potentially life-threatening 
clinical conditions (such as respiratory problems and sepsis) which is an important additional 
advantage. In a very important report from the USA, Abouk et al report a 33% reduction in mortality 
from CCHD in US states that had introduced POS compared with those where introduction had not 
yet occurred.  
When defining the most appropriate screening algorithm a balance must be struck between 
detection of serious illness and limiting false positive results and local circumstances may play an 
influence in this respect. More data from larger populations may help to refine further the screening 
algorithm. Finally, it is also important to remember that PO screening is not a perfect test and babies 
with CCHD may still be missed.15,16  Therefore PO screening should be used as an addition to existing 
screening methods and health care workers and parents need to be aware of the limitations of the 
test.   
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